<DOC>
	<DOCNO>NCT02175186</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ALBIS Gastroduodenal Mucosal Injury Patients Receiving Dual Antiplatelet Therapy Percutaneous Coronary Intervention .</brief_summary>
	<brief_title>Effect ALBIS Gastroduodenal Mucosal Injury Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<criteria>Age 20 80 year Patients undergo percutaneous coronary intervention need take dual antiplatelet therapy continuously least 12weeks Modified Lanza Score grade 01 measure upper gastrointestinal endoscopy mild gastrointestinal symptom Creatinen blood ≤ 3mg/dl BUN ≤ 50mg/dl Birilubin ≤ 3mg/dl AST ALT ≤ 80U/L Pregnant breast feed History Stomach esophagus surgery Peptic ulcer reflux esophagitis ZollingerEllison syndrome primary esophageal motility disorder Malignant tumor Bleeding tendency coagulopathy Contraindication ALBIS Long term use aspirin P2Y12 receptor antagonist within 1month Patients tool medicine PPI , APA , H2blocker , Muscarine receptor antagonist , antigastic agent , antacid , anticaogulant , Bisphosphonate agent , Cytotoxic drug , NSAID , adrenal cortex hormone agent ( topical treatment allow ) Terminal patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gastritis</keyword>
	<keyword>Gastroduodenal Ulcer</keyword>
	<keyword>Percutaneous Coronary Revascularization</keyword>
	<keyword>Dual Antiplatelet Therapy</keyword>
</DOC>